NCT03695757 is a Phase 1, PHASE2 clinical trial of Part A) Healthy subjects in Immunotherapy, sponsored by Ajou University School of Medicine.

Who is sponsoring NCT03695757?

NCT03695757 is sponsored by Ajou University School of Medicine.

What drugs are being tested in NCT03695757?

Interventions in NCT03695757: Part A) Healthy subjects, Part B) Advanced solid tumor.

What condition does NCT03695757 study?

NCT03695757 studies Immunotherapy.

Is NCT03695757 still recruiting?

NCT03695757 is currently completed. Last updated 6 July 2021.

Last reviewed 2021-07-06 · How we verify

NCT03695757

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG

Completed Phase 1, PHASE2 Last updated 6 July 2021

What this trial tests

Phase 1, PHASE2 trial testing Part A) Healthy subjects in Immunotherapy in 24 participants. Completed in 24 March 2021.

Timeline

6 November 2018

Primary endpoint
26 January 2021

24 March 2021

Quick facts

Lead sponsor	Ajou University School of Medicine
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	6 November 2018
Primary completion	26 January 2021
Estimated completion	24 March 2021
Sites	1 location across South Korea

Drugs / interventions tested

Part A) Healthy subjects — full drug profile →
Part B) Advanced solid tumor — full drug profile →

Conditions studied

Immunotherapy — all drugs for Immunotherapy →

Sponsor

Ajou University School of Medicine

Who can join

19 and older, any sex, with Immunotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this prospective pilot clinical study is to evaluate the safety and immunostimulatory effect of intramuscularly administrations of autologous total IgG (autologous total IgG therapy) in healthy subjects and patients with advanced solid tumor (non-small cell lung cancer, stomach cancer, colon cancer, ovarian cancer, breast cancer, pancreatic cancer, biliary cancer, melanoma, renal cell carcinoma etc.). In addition, antitumor effect of intramuscularly administrations of autologous total IgG in patients with advanced solid tumor will be also evaluated.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

B-Cell-Based Immunotherapy: A Promising New Alternative.
Gupta SL, Khan N, Basu S, Soni V. · · 2022 · cited 29× · PMID 35746487 · DOI 10.3390/vaccines10060879
Intramuscular administration of autologous total immunoglobulin G induces immunomodulatory effects on T cells in healthy human subjects: An open-labeled prospective single-arm trial.
Kwon B, Yang SJ, Cho SM, Kim ME, et al · · 2022 · cited 6× · PMID 35665739 · DOI 10.1097/md.0000000000029486

Verify or expand the search:

Other recruiting trials for Immunotherapy

Currently open trials in the same condition.

NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07458529 — Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT07436845 — Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arte · recruiting
NCT06671613 — Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer · NA · recruiting

Other Ajou University School of Medicine trials

Trials by the same sponsor.

NCT07101380 — Feasibility Study of 'SuperBrain BOOM' for Mild Cognitive Impairment Patients · NA · recruiting
NCT07395752 — Youth Suicide and Self-Harm Intervention: Clinical and Biological Outcomes Study · NA · recruiting
NCT06964217 — Immediate Fracture Risk After Antihypertensive Drug Initiation · not yet recruiting
NCT05751603 — Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex · NA · not yet recruiting
NCT07479160 — Heart to Heart Web-based Communication Program for Heart Failure · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03695757 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ajou University School of Medicine
Last refreshed: 6 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03695757.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing